在抗性上皮卵巢卵巢癌中,Olaparib和Palbociclib的协同作用
1Department of gynecology surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Cancer Hospital of Dalian University of Technology,N44 Xiaoheyan Road, Dadong distric, Shenyang 110042, Liaoning, People's Republic of China.
American journal of physiology. Cell physiology
|February 26, 2025
概括
这项研究表明,将多ADP-ribose聚合酶抑制剂 (PARPi) 与循环素依赖性激酶4/6抑制剂 (CDK4/6i) 结合起来,可以有效地减少耐药性上皮卵巢癌 (EOC) 的瘤生长. 这种组合疗法为克服PARPi耐药性的治疗提供了一个有希望的策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 表皮卵巢癌 (EOC) 常常会对多ADP-ribose聚合酶抑制剂 (PARPi) 产生耐药性.
- 了解PARPi耐药性的机制对于开发有效的治疗策略至关重要.
- 循环素依赖性激酶4/6抑制剂 (CDK4/6i) 正在成为癌症治疗中的潜在药物.
研究的目的:
- 研究EOC中PARPi耐药性的机制.
- 评估PARPi与CDK4/6i结合的疗效,以克服这种抵抗.
- 为了确定预测治疗反应的潜在生物标志物.
主要方法:
- 通过PARPi治疗开发了耐药的EOC细胞系 (A2780-ola-r,SKOV-3-ola-r).
- 用Olaparib (PARPi),Palbociclib (CDK4/6i) 和低剂量的组合治疗耐药细胞系.
- 生物信息学分析以确定潜在的治疗点.
- 细胞循环分析,免疫光学和西斑,以评估治疗对DNA修复途径和蛋白质表达的影响.
主要成果:
- 低剂量组合疗法显著降低了抗性EOC细胞系中的瘤细胞增殖.
- 组合治疗诱导了G1阶段细胞周期停止和改变了DNA损伤标志物 (减少RAD51,增加p-γH2AX).
- 生物信息学确定了KNSTRN和TRPC4AP作为潜在的标,TRPC4AP水平与治疗反应具有积极的相关性.
结论:
- 将PARPi与CDK4/6i结合在一起是克服EOC中PARPi抵抗的可行策略.
- KNSTRN和TRPC4AP可以作为这种组合疗法的有效性预测生物标志物.
- 这种方法有望改善对PARPi耐药的EOC患者的治疗结果.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combined Effects of Drugs: Synergism
3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.7K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K


